Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL

Optimal management of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) is dictated by patient characteristics, prior therapy, and response to prior therapy. We report the final analysis of combined fludarabine, cyclophosphamide, and rituximab (FCR) for previously treated patients...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Badoux, Xavier C., Keating, Michael J., Wang, Xuemei, O'Brien, Susan M., Ferrajoli, Alessandra, Faderl, Stefan, Burger, Jan, Koller, Charles, Lerner, Susan, Kantarjian, Hagop, Wierda, William G.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2011
Teme:
Clinical Trials and Observations
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123386/
https://ncbi.nlm.nih.gov/pubmed/21245487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-08-304683
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki